Hard on the heels of the disclosure that Merck KGaA is talking to SpringWorks about a possible takeover, a new FDA approval could have sweetened the deal. Stamford, Connecticut-based SpringWorks ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

In its 28th year, the annual MPW list recognizes 100 women leading major global companies. This year, 21 listees are at the ...

SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)’s sale to Merck KGaA, Darmstadt, Germany for $47.00 per share in cash. If you are a SpringWorks shareholder, click here to learn more about your ...

SpringWorks Therapeutics (SWTX) gains EMA panel endorsement for Mirdametinib, a treatment for neurofibromatosis type 1. Read ...

In a recent development, Antengene Corporation Limited announced a global clinical collaboration with Merck (NYSE:MRK) to evaluate ATG-022 in combination with KEYTRUDA®, which could enhance Merck ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...